Filing Flows › Aktis Oncology (AKTS) › Recalls, complaints & regulation
Aktis Oncology (AKTS): clinical trials
Aktis Oncology (AKTS) beyond its filings: 3 active clinical trials.
Aktis Oncology's latest quarter
Aktis Oncology, Q2 2026: revenue $3.4M (+111% year over year), operating margin -854.0%, net loss $24.1M, operating cash flow −$20.6M. The chart follows the revenue to costs, profit and cash.
Questions
How many clinical trials does Aktis Oncology have?
3 active studies on ClinicalTrials.gov, 0 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.